Literature DB >> 18834638

Mental confusion associated with scopolamine patch in elderly with mild cognitive impairment (MCI).

Sang Won Seo1, Mee Kyung Suh1, Juhee Chin1, Duk L Na2.   

Abstract

Mental confusion or delirium can occur after application of scopolamine patch. However, predisposing factors for scopolamine-induced delirium are not known. It is expected that undetected incipient dementia or mild cognitive impairment (MCI) may be prone to develop mental confusion after applying the scopolamine patch. For the past 5 years, we found seven elderly women who had experienced transdermal scopolamine-induced mental confusion. They underwent neuropsychological tests after recovery from mental confusion (mean duration from onset to the test: 66 days). The results showed that all the patients were impaired in at least one of cognitive domains, fulfilling the criteria of MCI. These findings suggest that scopolamine patch-induced mental confusion should be included in the differential diagnoses of mental confusion in elderly, especially in travel situation, and that older people with undetected MCI are prone to develop scopolamine patch-induced mental confusion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18834638     DOI: 10.1016/j.archger.2008.07.011

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  8 in total

1.  Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats.

Authors:  Amir H Rezvani; Marty Cauley; Hannah Sexton; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

2.  Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; Shahnawaz M Amdani; Zhenglan Chen; Ren-Qi Huang; John A Schetz
Journal:  Pharmacol Res       Date:  2016-05-06       Impact factor: 7.658

3.  Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

Authors:  Ricardo Alvarez-Jimenez; Geert Jan Groeneveld; Joop M A van Gerven; Sebastiaan C Goulooze; Anne Catrien Baakman; Justin L Hay; Jasper Stevens
Journal:  Br J Clin Pharmacol       Date:  2016-07-14       Impact factor: 4.335

4.  Association between prescribing of anticholinergic medications and incident delirium: a cohort study.

Authors:  Noll Campbell; Anthony Perkins; Siu Hui; Babar Khan; Malaz Boustani
Journal:  J Am Geriatr Soc       Date:  2011-11       Impact factor: 5.562

5.  Effects of chronic sazetidine-A, a selective α4β2 neuronal nicotinic acetylcholine receptors desensitizing agent on pharmacologically-induced impaired attention in rats.

Authors:  Amir H Rezvani; Marty Cauley; Yingxian Xiao; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2012-10-26       Impact factor: 4.530

6.  Scopolamine promotes neuroinflammation and delirium-like neuropsychiatric disorder in mice.

Authors:  So Yeong Cheon; Bon-Nyeo Koo; So Yeon Kim; Eun Hee Kam; Junhyun Nam; Eun Jung Kim
Journal:  Sci Rep       Date:  2021-04-16       Impact factor: 4.379

Review 7.  Gastroparesis: concepts, controversies, and challenges.

Authors:  Klaus Bielefeldt
Journal:  Scientifica (Cairo)       Date:  2012-08-08

8.  Scopolamine-induced "cholinergic stress test" in the elderly.

Authors:  Gustavo C Román; Robert E Jackson; E Mariana Longoria; Ronald E Fisher
Journal:  Front Pharmacol       Date:  2014-08-13       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.